Contact information

Prof. Dr. med. Björn Chapuy

Department of Hematology, Oncology and Tumorimmunology
Charité Universitätsmedizin Berlin
Campus Benjamin Franklin
Hindenburgdamm 30
12203 Berlin



Academic education

1997 - 2004 Medical School, University Medical Center Göttingen (UMG), Germany


Scientific degrees

2012 Junior Faculty/Instructor in Medicine, Dana-Farber Cancer Institute/Harvard Medical School (DFCI/HWS), Boston, MA, USA
2006 MD thesis, Department of Biochemistry/Cell Biology, UMG; Advisor: Prof. Dr. von Figura/Prof. Dr. S. Höning (Summa cum laude)
2004 Unlimited License to practice medicine in Germany
2004 Graduation from Medical School, UMG, Göttingen


Scientific career

2021 - present Attending physician, Dept. Hematology and Medical Oncology, UMG
2020 - present Board certification Internal Medicine, Hematology and Oncology
2019 - present Elected steering board member, German Lymphoma Alliance (GLA)
2019 - present Member, program committee aggressive lymphoma, German Society of Hematology and Oncology (DGHO)
2019 Member, Organizing Team, DGHO
2018 - present  Professor of Tumor Biology and Signal Transduction (W2tt), UMG
2018 - present  Clinical fellowship in Hematology and Oncology, UMG
2018 - present Coordination team, Else Kröner-Fresenius, Promotionskolleg, UMG
2009 - present Affiliated Member, Broad Institute, Cambridge, MA, USA
2012 - 2018 Junior Faculty/Instructor in Medicine, Lymphoma Program, DFCI/HMS, Boston, MA, USA
2008 - 2012 Postdoctoral fellow with Prof. Dr. M. Shipp, Lymphoma Program, DFCI/HWS, Boston, MA, USA
2004 - 2008 Research Associate with Prof. Dr. G. Wulf, Department of Hematology and Oncology, UMG
2004 - 2008 Combined residency and clinical fellowship in Hematology and Oncology, Department of Hematology and Oncology, UMG


Honors/ Awards/ Memberships

2020 - present Member, Reviewer, European Hematology Association (EHA)
2019 - present Member, eMED System Medicine Research Network, Ministry of Science
2018 - present Member, German Lymphoma Alliance
2018 Oncology Award, Gilead Science GmbH
2016 Medical Oncology Translational Grant Award, DFCI/HWS
2014 Claudia Adams Barr Award for Basic Cancer Research
2012 - 2015 German society for Hematology and Oncology (DGHO)
2010 - present Member, American Association for Cancer Research (AACR), USA
2008 - present Member, Reviewer, Moderator, American Society of Hematology (ASH), USA
2008 - 2010 Research fellowship, DFG
2006 Young investigator award, UMG
2004 - present Member, Reviewer, Moderator, German Society of Hematology & Oncology (DGHO)
2004 - present Member, German Society of Internal Medicine (DGIM)


  • Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies

    Genetic alterations in the DNA damage response (DDR) pathway are a frequent mechanism of resistance to chemoimmunotherapy (CIT) in B-cell malignancies. We have previously shown that the synergy of CIT relies on secretory crosstalk elicited by chemotherapy between the tumor cells and macrophages.…

  • Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

    In patients with chronic lymphocytic leukemia, Richter transformation (RT) reflects the development of an aggressive lymphoma that is associated with poor response to chemotherapy and short survival. We initiated an international, investigator-initiated, prospective, open-label phase 2 study in…

  • An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL

    himeric antigen receptor T cell (CAR T) therapy is a potent treatment for relapsed/refractory (r/r) B cell lymphomas but provides lasting remissions in only ∼40% of patients and is associated with serious adverse events. We identify an upregulation of CD80 and/or CD86 in tumor tissue of (r/r)…

  • Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

    Primary mediastinal large B-cell lymphomas (PMBLs) are aggressive tumors that typically present as large mediastinal masses in young women. PMBLs share clinical, transcriptional, and molecular features with classical Hodgkin lymphoma (cHL), including constitutive activation of nuclear factor κB…

    Link to the publication
  • Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

    Tumour heterogeneity encompasses both the malignant cells and their microenvironment. While heterogeneity between individual patients is known to affect the efficacy of cancer therapy, most personalized treatment approaches do not account for intratumour heterogeneity. We addressed this issue by…

  • Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

    Genomic profiling revealed the identity of at least 5 subtypes of diffuse large B-cell lymphoma (DLBCL), including the MCD/C5 cluster characterized by aberrations in MYD88, BCL2, PRDM1, and/or SPIB. We generated mouse models harboring B cell–specific Prdm1 or Spib aberrations on the background of…